Compare Crocs, Inc. (CROX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Crocs, Inc. trades at $117.45 (market cap $5.60B), while Zimmer Biomet Holdings Inc trades at $89.07 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3× Crocs, Inc.'s market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| CROX | ZBH | |
|---|---|---|
Market Cap | $5.60B | $16.95B |
Volume | 1,026,773 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $103.98 |
52-Week Low | $73.39 | $79.58 |
Typical Hold Time | 96 Days | 89 Days |
Enterprise Value | $7.12B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $115.20, down 4.18% amid bearish technical signals, though recent earnings beats and a 51% analyst buy rating suggest underlying strength. The stock shows attractive valuation with a P/E of 10.37 and strong profitability metrics including 57.47% gross margin and 42.3% ROE. Management is focusing on product innovation and HEYDUDE brand reset to drive growth.
Despite near-term price pressure, CROX offers value with consensus price target of $136.78 (19% upside). Risks include recent net income decline to -$81M and competitive pressures in footwear. The company's cash flow generation and brand positioning support long-term recovery potential.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
